Danaher Corporation Acquires Abcam plc for $5.7 Billion

Danaher Corporation Acquires Abcam plc for $5.7 Billion

by | Aug 28, 2023 10:50 am | Laboratories, MRI & Dialysis

Danaher Corporation announced on August 28 that it has entered into a definitive agreement to acquire Abcam plc. According to data captured in the LevinPro HC database, this acquisition represents the 94th Laboratories, MRI and Dialysis transaction of 2023.  Danaher will acquire all the currently outstanding shares of Abcam at a price of $24.00 per share in cash. In total, this acquisition is valued at approximately $5.7 billion, which factors in assumed debts and deducts acquired cash.  Abcam Plc is a global life science company, which distributes antibodies and associated protein research tools. Its products include primary and secondary antibodies, proteins, peptides, lysates,... Read More »
Danaher Corporation Buys Aldevron

Danaher Corporation Buys Aldevron

by | Jun 22, 2021 10:29 am | Laboratories, MRI & Dialysis

The medical device giant Danaher Corporation (NYSE: DHR) is back with a new acquisition valued at nearly $10 billion. The company is buying Aldevron for $9.6 billion from private equity firm EQT Partners. Founded in 1998, Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. The business employs 600 people. No other financials for Aldevron were disclosed. The deal was financed by using cash on hand and/or proceeds from the issuance of commercial paper.  Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment. The... Read More »
Danaher Drops Business Segments to Appease Regulators

Danaher Drops Business Segments to Appease Regulators

by | Oct 28, 2019 2:20 pm | Medical Devices, Pharmaceuticals

Danaher Corporation (NYSE: DHR) is selling a number of its business segments and assets to Sartorius AG (FWB: SRT) for $750 million. The sale includes Danaher’s label-free biomolecular charaterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses, which are part of its Life Sciences segment. Danaher is selling this portion of its Life Sciences segment as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business (NYSE: GE). These businesses generated approximately $140 million in combined revenue in 2018. GE Life Sciences announced the sale of its biopharmaceutical business for $21.4... Read More »

Danaher Doubles Down on Blood Diagnostics

by | Sep 9, 2016 3:08 pm | Biotechnology

Danaher Corporation (NASDAQ: DHR) has set a new direction for itself, after spinning off its Test & Measurement segment, Industrial Technologies segment and its Retail/Commercial Petroleum platform into Fortive Corporation (NYSE: FTV) on July 2. Post-separation, the company is positioned as a global science and technology  innovator with more than 20 operating companies in the health care, environmental and industrial industries. In September, Danaher announced its acquisition of Cepheid (NASDAQ: CPHD ) for $3.9 billion, or $53.00 per share. The consideration represents approximately a 54% percent premium to Cepheid’s common stock over the closing price of $34.42 on September 2,... Read More »